Target Price | $10.67 |
Price | $7.07 |
Potential |
50.87%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target NeoGenomics, Inc. 2026 .
The average NeoGenomics, Inc. target price is $10.67.
This is
50.87%
register free of charge
$15.00
112.16%
register free of charge
$7.50
6.08%
register free of charge
|
|
A rating was issued by 15 analysts: 8 Analysts recommend NeoGenomics, Inc. to buy, 7 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the NeoGenomics, Inc. stock has an average upside potential 2026 of
50.87%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 660.57 | 744.75 |
11.65% | 12.74% | |
EBITDA Margin | -7.51% | 7.33% |
26.58% | 197.56% | |
Net Margin | -11.92% | -10.93% |
19.84% | 8.29% |
15 Analysts have issued a sales forecast NeoGenomics, Inc. 2025 . The average NeoGenomics, Inc. sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an NeoGenomics, Inc. EBITDA forecast 2025. The average NeoGenomics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 NeoGenomics, Inc. Analysts have issued a net profit forecast 2025. The average NeoGenomics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.62 | -0.63 |
11.43% | 1.61% | |
P/E | negative | |
EV/Sales | 1.47 |
10 Analysts have issued a NeoGenomics, Inc. forecast for earnings per share. The average NeoGenomics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
NeoGenomics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Locked
➜
Locked
|
Locked | May 06 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | May 01 2025 |
Leerink Partners |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
Needham |
Locked
➜
Locked
|
Locked | Apr 29 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
Analyst Rating | Date |
---|---|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 06 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 01 2025 |
Locked
Leerink Partners:
Locked
➜
Locked
|
Apr 30 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 30 2025 |
Locked
Needham:
Locked
➜
Locked
|
Apr 29 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.